Nurix Therapeutics saw the highest growth of 1.99% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.42% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Nurix Therapeutics’s patent filings and grants. Buy the databook here.
Nurix Therapeutics has been focused on protecting inventions in United States(US) with four publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 9% filings and 100% grants. The Australia(AU), European Patent Office(EPO), Israel(IL), and United States(US) patent Office are among the top ten patent offices where Nurix Therapeutics is filings its patents. Among the top granted patent authorities, Nurix Therapeutics has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Nurix Therapeutics
Patents related to cell & gene therapy lead Nurix Therapeutics's portfolio
Nurix Therapeutics has the highest number of patents in cell & gene therapy. For cell & gene therapy, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Lymphoma related patents lead Nurix Therapeutics portfolio followed by leukemia, and lyme disease
Nurix Therapeutics has highest number of patents in lymphoma followed by leukemia, lyme disease, ulcerative colitis, and preleukemia. For lymphoma, nearly 1% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Nurix Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.